A series of chromone-3-carbaldehydes have been prepared using Vilsmeier-Haack methodology while a corresponding series of chromone-2-carbaldeydes have been synthesized via the Kostanecki-Robinson reaction. Baylis-Hillman reactions have been conducted on both series of chromone carbaldehydes using three different catalysts, viz., 1,4-diazabicyclo(2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec- 7-ene (DBU) and 3-hydroxyquinuclidine (3HQ), and acrylonitrile, methyl acrylate and methyl vinyl ketone as the activated alkenes. These reactions have typically (but not always!) afforded both normal Baylis-Hillman and dimeric products. Attention has also been given to the use of 1-methyl-2-pyrrolidine (1-NMP), an ionic liquid, to replace normal organic solvents, and it has been found that, in the presence of DABCO, chromone-3-carbaldehydes afford the dimeric products alone. Reactions of chromone-3-carbaldehydes with methyl vinyl ketone have yielded unexpected, novel adducts, which appear to arise from preferential attack at C(2) in the chromone nucleus. Research on chromone-2-carbaldeydes under Baylis-Hillman conditions has also resulted in the formation of some interesting products instead of the expected Baylis-Hillman adducts. The Baylis-Hillman products have been explored as substrates for aza-Michael reactions using various amino derivatives including protected amino acids in the presence of the tetrabutylammonium bromide (TBAB) and the ionic liquid, 3-butyl-1- methylimidazoleboranetetrafluoride (BmimBF₄), as catalysts. The aza-Michael products have been targeted as truncated ritonavir analogues for investigation as potential HIV -1 protease inhibitors, and representative compounds have been subjected to enzyme inhibition assays to explore the extent and type of inhibition. Lineweaver-Burk and Dixon plots have indicated competitive inhibition in one case as well as non-competitive inhibition in another, and the inhibition constants (Ki) have been compared with that of the ritonavir. Computer modelling studies have also been conducted on selected chromonecontaining derivatives, using the ACCELRYS Cerius² platform. Interactive docking of the chromone-containing ligands into the HIV -1 protease receptor site, using the Ligandfit module, has indicated the importance of hydrogen-bonding interactions mediated by bridging water molecules situated in the receptor cavity. NMR spectroscopy has been used to elucidate complex and competing mechanistic pathways involved in the Baylis-Hillman reactions of selected 2-nitrobenzaldehydes with MVK in the presence of DABCO - reactions which afford the normal BaylisHillman product, the MVK dimer and syn- and anti-Baylis-Hillman type diadducts. The kinetic data confirm the concomitant operation of two pathways and reveal that, in the initial stage of the reaction, the product distribution is kinetically controlled, whereas in the latter stage, thermodynamic control results in the consumption of the normal Baylis-Hillman product and predominance of the anti-diadduct.

Motivées par l'observation mondiale de l'augmentation de la morbidité et de la mortalité associées à des pathologies liées à l'obésité, dont la stéatose, les études pré-cliniques et cliniques s'intéressent à la recherche de nouveaux biomarqueurs pour le diagnostic de la stéatose. Actuellement, la stéatose est diagnostiquée et gradée par des analyses histologiques à partir d'une biopsie du foie. Dans l'intérêt du patient, et afin de permettre un suivi de la stéatose lors d'un régime ou d'un traitement, il est apparu important de se tourner vers des modalités de diagnostic moins invasives. Dans ce cadre, la spectroscopie par résonance magnétique (SRM), non-invasive et non-ionisante, est une méthode de choix pour le diagnostic de la stéatose par la mesure de la fraction lipidique hépatique. De plus, à partir des informations observables sur un spectre de SRM acquis au niveau hépatique, il est possible d'envisager une quantification de la composition en acides gras (AG) des lipides hépatiques, potentiel biomarqueur pour le suivi d'une stéatose. Les travaux de cette thèse ont été réalisés à partir d'objets-tests, et dans le cadre d'études pré-cliniques (4,7 T) et cliniques (3,0 T). Une étude du protocole d'acquisition de spectres de SRM pour la quantification de la composition en AG des lipides a été réalisée, avec notamment un questionnement quant à la nécessité de l'utilisation d'un module de suppression du signal de l'eau. Un état de l'art des algorithmes de quantification de la composition en AG des lipides a été effectué, et des tests de validations de ces algorithmes ont été réalisés afin de déterminer le plus approprié à la problématique hépatique, dans nos conditions expérimentales. Enfin, toujours dans l'objectif de déterminer des nouveaux biomarqueurs de la stéatose, une méthode de mesure par SRM in vivo du T1 de l'eau et de la résonance majeure des lipides hépatiques (LOREEDE pour LOngitudinal RElaxation time Evaluation from Dynamic Equilibrium) a été développée, et validée au cours d'une étude préliminaire sur des objets-tests et in vivo sur modèles murins. / In recent years, there has been an unprecedented increase in the morbidity and mortality associated with diseases such as the steatosis, linked to obesity. In this context, pre-clinical and clinical studies are of interest in the search for new biomarkers allowing the diagnosis of steatosis. Currently, steatosis is diagnosed and graded by histological analyzes from a liver biopsy. On the other hand, it is advantageous to use non-invasive diagnostic modalities, especially in longitudinal studies. In this context, magnetic resonance spectroscopy (MRS), as a non-invasive and non-ionizing approach, is an attractive alternative method for the diagnosis of steatosis by measuring the hepatic fat fraction. Moreover, from the MRS spectrum acquired in the liver, it is possible to quantify the fatty acids (FA) composition of the hepatic lipids, which could be a potential biomarker for the follow-up of steatosis. The work of this thesis has been performed in vitro and in vivo, in the context of pre-clinical (4.7 T) and clinical (3.0 T) studies. An investigation of the optimal MRS acquisition protocol for the quantification of FA was carried out, with particular attention to the role of the water signal suppression module. Different quantification algorithms of the lipid composition were studied and validation of these algorithms was carried out in vitro and in vivo. Finally, still with the objective of determining new biomarkers of steatosis, a method (LOREEDE: LOngitudinal RElaxation time Evaluation from Dynamic Equilibrium) for the measurement in vivo of the T1 of the water resonance and the major lipid resonance, by MRS, was developped and validated in a preliminary study.

Ce manuscrit de thèse est dédié aux calculs quantiques de paramètres de spectroscopie de résonance magnétique nucléaire (RMN) de métaux de transition dans des composés inorganiques de l’état solide. Le manuscrit est divisé en cinq parties. La première partie présente les atouts de la spectroscopie RMN en tant que technique d’investigation de composés inorganiques de l’état solide. Dès lors que le noyau sondé est un métal de transition, l’expérience doit être complétée par des calculs quantiques afin d’interpréter au mieux les données expérimentales. La seconde partie du manuscrit est dédiée à la description de la RMN et des outils méthodologiques utilisés dans ce travail. Le troisième chapitre est dédié au calcul du déplacement chimique de l’isotope 95 du molybdène dans des clusters halogénés de formule [Mo6X14]2- (X = Cl, Br, I). Une attention particulière est donnée à l’influence des effets de solvatation sur le calcul. Le quatrième chapitre est dédié à l’étude des composés A6Re3Mo3S8(CN)5 (A = K, Cs) dont la structure cristallographique est basée sur un motif octaédrique hétéronucléaire Re3Mo3S8(CN)6. La résolution structurale par diffraction des rayons X sur monocristal n’ayant pas permis de résoudre le problème de la distribution des métaux de transition dans l’octaèdre, une étude spectroscopique in silico sur la base de calculs DFT moléculaires et périodiques a été entreprise. Dans le dernier chapitre, des composés hétéronucléaires de formule [Ln6-6xLn6xO(OH)8(NO3)6(H2O)12]2+ (Ln = Pr-Lu, Y) ont été étudiés du point de vue théorique afin de mieux comprendre les données spectroscopiques collectées. / This work is devoted to the calculations of nuclear magnetic resonance (NMR) parameters of transition metal nuclei in inorganic solid-state materials using first-principles calculations. The manuscript is divided in five chapters. The first one shows that NMR is an interesting spectroscopic method to gain some information on the properties of inorganic materials. As far as the probed nucleus is a transition metal, experiments must be completed with quantum chemical calculations in order to better interpret the spectroscopic data. The second chapter is devoted to the quantum chemical tools that are necessary to the understanding of this work are presented. The third chapter deals with the computations of 95Mo NMR parameters of [Mo6X14]2- (X = Cl, Br, I) octahedral clusters. A special attention is paid to the influence of solvation effects on the computed NMR parameters. The fourth chapter is devoted to the study of A6Re3Mo3S8(CN)5 (A = K, Cs) compounds. Their crystal structures are based on a heteronuclear octahedral motif Re3Mo3S8(CN)6. Since X-ray diffraction refinements did not solve the colouring problem in the octahedron, an in silico spectroscopic study has been carried out using molecular and periodic DFT calculations. The last chapter of this report deals with heteronuclear polyoxolanthanides that have been studied using first-principles calculations in order to better understand their 89Y NMR spectra.

No description available.

Xanthomonas axonopodis pv citri (Xac) é uma bactéria fitopatógênica que causa de cancro cítrico em plantações no mundo inteiro. Trinta e cinco proteínas alvo foram selecionadas para estudos de proteômica estrutural a partir do genoma de Xac. As proteínas foram clonadas, expressas e testadas usando uma nova metodologia de triagem de proteínas que permite que espectros de RMN 2D 15N-HSQC sejam coletados antes da purificação da proteína em estudo. Esta abordagem possibilitou determinar quais proteínas alvo melhor se adequavam para estudos estruturais futuros por RMN e/ou cristalografia de raios X de forma rápida e eficaz. A proteína ClpS de Xac, descrita como moduladora da atividade da protease bacteriana ClpAP, foi uma das proteínas selecionadas para estudos estruturais por RMN usando esta metodologia. O assinalamento das ressonâncias da cadeia principal e das cadeias laterais desta proteína usando experimentos de tripla ressonância e dados de dinâmica e de troca H/D forneceram informações sobre a sua estrutura secundária. Um modelo tridimensional foi gerado por modelagem por homologia a partir de um homólogo de E. coli e foi validado por acoplamentos dipolares residuais (DHN ) obtidos experimentalmente. Todos os dados RMN sugerem que a região N-terminal de ClpS se apresenta desestruturada. O mapeamento por RMN da interação de ClpS com a sua parceira ClpA é também apresentado. / Xanthomonas axonopodis pv citri (Xac) is a phytopathogenic bacterium that causes citrus canker around the world. Thirty-five target proteins for structural proteomics studies have been selected from the Xac genome. The target proteins were cloned, expressed and tested using a novel screening methodology that allows for 2D 15N-HSQC NMR spectra to be collected prior to the purification of the target protein. This approach allowed us to determine which target proteins were amenable for future structural studies by NMR and/or X-ray crystallography in a fast and efficient manner. The ClpS protein, which has been described as a modulator of substrate specificity of the bacterial protease ClpAP, was one of the proteins selected structural studies by NMR using this methodology. Backbone and side-chain assignment derived from 3D triple resonance NMR experiments and dynamic data from hydrogen-deuterium exchange NMR experiments have provided information on the secondary structure elements of this protein. A model for Xac ClpS was generated by homology modeling from an E. coli homogue and validated using experimentally obtained DHN residual dipolar couplings. All NMR data suggest that the N-terminal region of the protein ClpS is highly unstructured. NMR mapping of the interaction of ClpS with its partner protein ClpA is also presented.

Le but de la thèse était d'étudier la sensibilité de nouveaux biomarqueurs RMN visant à quantifier les changements pathologiques dans le muscle dystrophique. La dystrophie musculaire (DM) désigne un groupe hétérogène de maladies avec une atrophie musculaire progressive associée à un état de faiblesse. Elle est caractérisée par des degrés variables de nécrose, de régénération, de troubles de l'homéostasie ionique, d'inflammation chronique et finalement par le remplacement des muscles par du tissu fibro-graisseux. Mon objectif était d’évaluer la RMN du ²³Na et les techniques avancées de mesure du temps de relaxation transversal ¹H (T₂) en tant que des biomarqueurs sensibles et précoces. La RMN du ²³Na mesure les concentrations de sodium étroitement contrôlées et donne sa distribution dans le tissu. Cette information peut être utilisée pour évaluer l'homéostasie ionique et l'intégrité cellulaire. Cependant, la concentration in vivo en ²³Na est faible, la RMN du ²³Na souffre donc d'une faible sensibilité par rapport à ¹H. L’altération du T₂ ¹H du muscle, communément interprétée comme un indicateur de l'activité de la maladie, est liée à une variété d’événements non-spécifiques tels que l'œdème, l'inflammation ou la nécrose, qui précèdent le remplacement musculaire par la graisse. Des protocoles comprenant diverses méthodes de RMN du ²³Na et de ¹H T₂ ont été mis en œuvre pour évaluer les tissus musculaires squelettiques sains et dystrophiques sur des modèles animaux et sur patients. Ce travail fournit des preuves que la RMN du ²³Na pourrait offrir un biomarqueur sensible capable de surveiller l'altération spécifique du muscle dystrophique à un stade très précoce. / The aim of the thesis is to investigate the sensitivity of novel NMR outcome measures (OM) aiming to quantify pathological changes in the dystrophic muscle. Muscular dystrophy (MD) refers to a heterogeneous group of diseases with progressive muscle wasting and associated weakness characterized by variable degrees of necrosis, regeneration, ionic homeostasis disturbances, chronic inflammation, and, ultimately, resulting in the replacement of muscles by fibro-fatty tissue. My focus was on the evaluation of ²³Na NMR and advanced ¹H transverse relaxation time (T₂) techniques as early, sensitive OM. ²³Na NMR measures the tightly controlled sodium concentrations and distribution in skeletal muscle tissue. This biophysical information can be used to assess ion homeostasis and cell integrity. However, ²³Na NMR suffers from a low sensitivity and in vivo concentration compared to ¹H. Alterations in the muscle ¹H T₂, commonly interpreted as an indicator of disease activity, are linked to a variety of non-specific events like oedema, inflammation, or necrosis that precede the actual muscle replacement by fat. Protocols including different ²³Na NMR and ¹H T₂ methods were implemented to evaluate healthy and dystrophic skeletal muscle tissues of animal models and patients. This work provides evidence that ²³Na NMR could offer a sensitive outcome measure able to monitor specific alteration of the dystrophic muscle at a very early stage.

No description available.

Many proteins are unstable in solution and must be formulated in the solid state. This has led to an increase in the use of lyophilized dosage forms. Lyophilization is a complicated processing method consisting of three major steps: freezing, primary drying, and secondary drying. This can lead to several formulation stability challenges including changes in ionization within the matrix, phase separation of the protein drug from added stabilizers, sufficient mobility within the system for movement of reactive species and protein side chains, and crystallization of excipients upon storage. Solid-State Nuclear Magnetic Resonance Spectroscopy (SSNMR) is used to characterize many important properties of lyophilized formulations including crystalline vs. amorphous content, polymorphic form, ionization profile, interaction between formulation components with domain sizes, and mobility within the cake matrix. In order to study ionization changes in lyophilized solids, SSNMR and UV/Vis Diffuse Reflectance spectroscopy were used. 13C-labeled fumaric, succinic, and butyric acids were added to formulations at various pH levels, and were used to quantify change in the ionization of the matrix by monitoring the ionization ratios of the carboxylic acid peaks using SSNMR. pH indicators were also added to the formulations and their ionization ratio was determined using UV/Visible Diffuse Reflectance Spectroscopy. The ionization profile in the solid state was compared with that in solution before lyophilization. A rank ordering of ionization shift was made in pharmaceutically relevant buffers. SSNMR proton relaxation times (1H T1 and 1H T1rho) for each formulation component can be compared to determine homogeneity within the lyophilized matrix. The concept of spin diffusion is used in order to determine the length scale on which the components are either homogeneous or phase separated. The domain size is typically 20-50 nm or 2-10 nm for 1H T1 and 1H T1rho, respectively. PVP and dextran polymers were phase separated on both domains for physical mixtures and lyophilized mixtures. BSA and lysozyme were both lyophilized with formulations containing sucrose, trehalose, or mannitol as the stabilizer. Mannitol crystallized, and the relaxation times showed phase separation. Sucrose and trehalose both formed homogeneous systems at both length scales when formulated in a 1:1 ratio with BSA or lysozyme. Aspartame was shown to be phase separated from trehalose. The SSNMR proton relaxation times were also used to measure the local mobility in the lyophilized matrix, as a timescale of picoseconds to nanoseconds is associated with the 1H T1 relaxation time. Mobility was monitored in formulations containing a fixed amount of sucrose and mannitol, but with a variable amount of an IgG2 protein. The 1H T1 relaxation times decreased as protein content increased. The formulations with the highest relaxation time (lowest mobility), was the most stable in accelerated temperature conditions as monitored by size exclusion chromatography and capillary isoelectric focusing. This method can be used to rank order the most stable formulations at time-zero. Anti-plasticization was also studied by formulating sorbitol in various ratios with trehalose. The 1H T1 relaxation times increased with increasing sorbitol content, while the glass transition temperature decreased. Sorbitol and trehalose glasses were also exposed to different temperature storage conditions. Sorbitol appears to promote aging, as the formulations with higher sorbitol content showed larger increases in proton relaxation time.

In vivo proton magnetic resonance spectroscopy (1H MRS) is the only method available to measure small-molecule metabolites in living human tissue, including the brain, without ionizing radiation or invasive medical procedures. Despite its attendant potential for supporting clinical diagnostics in a range of neurological and psychiatric conditions, the metabolite concentration estimates produced by 1H-MRS experiments, and therefore their sensitivity and specificity to any particular biological phenomenon under study, are readily distorted by a number of confounds. These include but are not limited to static and radiofrequency field characteristics, signal relaxation dynamics, macromolecule and lipid contributions to the spectral baseline, spectral fitting artifacts, and other uncontrolled idiosyncrasies of 1H-MRS data acquisition, processing, and quantification. Using 1H-MRS data obtained via 3-Tesla and 7-Tesla magnetic resonance (MR) scanners from healthy controls, individuals with progressive and relapsing-remitting multiple sclerosis (MS), and individuals with post-traumatic stress disorder (PTSD) and/or major depressive disorder (MDD), this work therefore aims to build and apply a framework for quantifying and thereby reducing such confounds introduced to 1H-MRS estimates of in vivo metabolite concentrations at the steps of data processing and quantification, with an ultimate aim to maximizing the potential of 1H MRS for supporting sensitive and specific clinical diagnosis of neurological or psychiatric disease. The steps examined include spectral quantification by linear combination modeling (Chapter 2), absolute quantification by internal concentration referencing (Chapter 3), and cross-sectional statistical analysis of results (Chapters 4 and 5). Chapter 2 designs and implements a graphical user interface (GUI)-supported validation pipeline for measuring how data quality, spectral baseline, and baseline model affect the precision and accuracy of 1H-MR spectral quantification by linear combination modeling. This validation pipeline is then used to show that spectral data quality indices signal to noise ratio (SNR) and full width at half maximum (FWHM) interact with spectral baseline to influence not only the precision but also the accuracy of resultant metabolite concentration estimates, with fit residuals poorly indicative of true fit error and spectral baselines modeled as regularized cubic splines not significantly outperformed by those employing simulated macromolecules. A novel method for extending the commonly used spectral quantification precision estimate Cramér-Rao Lower Bound (CRLB) to incorporate considerations of continuous and piecewise polynomial baseline shapes is therefore presented, tested, and similarly integrated into a GUI-supported toolkit to improve the correspondence between estimated CRLB and metabolite fit error variability when this now empirically justified approach to spectral baseline modeling is used. In Chapter 3, age- and disease-associated differences in transverse (T2) water signal relaxation measured at 7 Tesla in the prefrontal cortex of individuals with progressive (N=21) relative to relapsing-remitting (N=26) or no (N=25) multiple sclerosis are shown to influence absolute quantification of metabolite concentrations by internal referencing to water. In Chapter 4, these findings from Chapters 2 and 3 are used to justify an evidence-based 1H-MR spectral processing and quantification protocol that focuses optimization efforts on baseline modeling approach and references metabolite concentration estimates to internal creatine instead of water. When this protocol is applied to 7-Tesla prefrontal cortex 1H-MR spectra from the aforementioned multiple sclerosis and control cohorts, it supports metabolite concentration estimates that, in the absence of any additional supporting data, inform supervised-learning-enabled identification of progressive multiple sclerosis at nearly 80% held-out validation sensitivity and specificity. Finally, in Chapter 5, the same processing, quantification, and machine-learning pipeline employed in Aim 3 is independently applied to a new set of 7-Tesla prefrontal cortex 1H-MRS raw data from an entirely different cohort of individuals with (N=20) and without (N=18) PTSD and/or comorbid or primary MDD. Here the processing, quantification, and statistics procedures designed using lessons in Chapters 2 and 3 and optimized for classifying multiple sclerosis phenotype in Chapter 4 generalize directly to metabolite-only classification of PTSD and/or MDD with sensitivity and specificity similarly near to or greater than 80%. In both Chapters 4 and 5, supervised learning avoids dimensionally reducing metabolite feature sets in order to pinpoint the specific metabolites most informative for identifying each disease group. Taken together, these findings justify the potential and continued development of 1H MRS, at least as applied in the human brain and especially as supported by multivariate approaches including supervised learning, as an auxiliary or mainstay of clinical diagnostics for neurological or psychiatric disease.

TCTP est une petite protéine globulaire (20~kDa) qui interagit avec de nombreux partenaires et qui est impliquée dans diverses fonctions cellulaires et physiologiques, avec un rôle bien documenté dans la réversion tumorale qui est un phénomène rare et spontané où une cellule cancereuse perd tout ou partie de son phénotype malin et retrouve des caractéristiques associées aux cellules bénignes telles que la sensibilité à l'apoptose. Dans les cellules cancéreuses, TCTP inhibe la dégradation de MDM2, diminuant ainsi les niveaux de p53 et favorisant le maintien et la progression du cancer. TCTP contient également un motif BH3-like connu pour réguler les membres de la famille Bcl-2 et elle interagit directement avec Bcl-xL et Mcl-1 pour renforcer leurs propriétés anti-apoptotiques. Dans la structure TCTP, le motif BH3-like n'est pas facilement accessible pour une interaction avec un partenaire. Conformément à son importance dans le maintien de la tumeur, TCTP est une cible pharmacologique validée dans le traitement du cancer et fait l’objet d’essais cliniques en cours avec une molécule d'abord connue comme anti-depresseur, la sertraline. Cependant, on en sait peu sur la structure de TCTP en complexe avec ses partenaires, ce qui entrave le développement de médicaments et ne permet pas de comprendre comment TCTP peut s'adapter à une telle variété de partenaires. Ainsi, nous avons étudié le mécanisme moléculaire par lequel TCTP s'associe à des protéines et à des ligands en utilisant diverses méthodes biophysiques (RMN, SAXS, CD, SEC, DSF...). Nous avons démontré que la protéine TCTP se lie à Bcl-xL et à Mcl-1 dans le sillon de liaison des motifs BH3. Dans les complexes, la région BH3-like est engagée dans l'interface intermoléculaire et la structure centrale de TCTP est déstabilisée dans un état de globule fondu (molten-globule). Nous avons en outre montré que seule une forme mineure pré-existante de TCTP, à savoir TCTP*, est compétente pour les interactions avec les partenaires Bcl-xL et Mcl-1. Dans TCTP*, la région BH3-like est détachée du domaine structuré et elle est accessible aux protéines Bcl-xL/Mcl-1 tandis qu'on retrouve un état globule fondu dans la partie globulaire de TCTP*. Nous avons également collecté des données d'interaction préliminaires entre TCTP et la sertraline, des ARN, la protéine YB-1 se liant à l'ARN et le domaine N-terminal de MDM2. Enfin, nous avons caractérisé TCTP phosphorylé (pTCTP) au résidu S46 en utilisant la Plk-1 car cette modification a un impact sur les interactions et est un marqueur de l'aggressivité tumorale. En résumé, ces travaux ont établi la versatilité de TCTP en terme de structure et ont montré que cette versatilité est indispensable pour exercer ses fonctions cellulaires. En conséquence, ceci devrait être pris en compte dans les stratégies de développement de nouvelles molécules thérapeutiques ciblant TCTP. / TCTP is a small (20~kDa) globular protein that interacts with many partners with consequences in various cellular and physiological functions, with well-documented roles in tumoral reversion program. Cells that undergo such program spontaneously loose their malignant phenotype and recover characteristics associated with benign cells, such as apoptosis. In cancer cells, TCTP inhibits MDM2 degradation, thus decreasing p53 levels and favoring tumor maintenance and progression. TCTP also contains a BH3-like motif known to regulate Bcl-2 family members and TCTP directly interacts with Bcl-xL and Mcl-1 to reinforce their pro-survival properties. In TCTP structure, the BH3-like motif is not readily accessible for interaction. Consistently with its importance in tumor maintenance, TCTP is a validated pharmacological target in cancer treatment with ongoing clinical trials using the TCTP-targeting antidepressant drug sertraline. However, little is known about TCTP structure in complex with partners, thus impeding the development of drugs and the understanding of how TCTP could adapt to its myriad of partners. Thus, we investigated the molecular mechanism by which TCTP associates with proteins and ligands using various biophysical methods (NMR, SAXS, CD, SEC, DSF...). We have demonstrated that full length TCTP binds to Bcl-xL and Mcl-1 in their BH3-binding groove. In the complexes, the TCTP BH3-like region is engaged in the intermolecular interface and the core TCTP structure is destabilized into a molten-globule (MG) state. We further showed that only a minor pre-existing form of TCTP, namely TCTP*, is competent for interactions with the Bcl-2 protein partners. In TCTP*, the BH3-like region is unpinned and accessible to Bcl-xL/Mcl-1 proteins and the core structure is also in MG state. We also collected preliminary interaction data between TCTP and sertraline, RNA, the RNA binding YB-1 protein and the MDM2 N-terminal domain. Finally, we characterized the Plk-1-mediated S46 phosphorylated TCTP (pTCTP), a marker of tumor aggressivity and its interaction properties. Overall, this work established the structural versatility of TCTP that is mandatory to exert its cellular functions and this versatility should be taken into account in drug-design strategies targeting TCTP.